• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

    38.26 -0.02 (-0.05%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 759,913
    Open 37.82
    Bid (Size) 37.50 (1,500)
    Ask (Size) 39.90 (500)
    Prev. Close 38.28
    Today's Range 37.30 - 38.84
    52wk Range 16.18 - 50.81
    Shares Outstanding 36,130,121
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup ↗
    Via Chartmill
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire

    Performance

    52-Week Range 24.7% below 52-week high
    38.26
    16.1852W Low 50.8152W High
    1 Week 8.8% below 1-week high
    34.181W Low 41.931W High

    UroGen Pharma Ltd. - Ordinary Shares (URGN) traded between $16.18 and $50.81 over the past 52 weeks and last traded at $38.26, 24.7% below its 52-week high. Over the past week it ranged between $34.18 and $41.93.

    Past 12 Months
    -6.0%
    -10.3%
    -2.4%
    +80.3%
    +68.5%
    +128.3%
    1W -$2.44
    1M -$4.38
    3M -$0.93
    6M +$17.04
    YTD +$15.55
    1Y +$21.50

    URGN was +128.3% over the past year, +80.3% over six months, +68.5% year to date, -6.0% in the last week.

    12 Months vs Market
    URGN
    +128.3%
    DIA
    +12.1%
    SPY
    +17.3%
    QQQ
    +23.5%
    IWM
    +13.2%

    Over the past 12 months URGN returned +128.3% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.2%.

    Volume & Liquidity 0.85× 3-mo avg
    Today 759,913 3-mo avg 889.7K
    1W
    1.5M
    1M
    945.7K
    3M
    889.7K
    6M
    851.1K
    YTD
    824.7K
    1Y
    870.5K

    URGN most recently traded 759,913 shares against a 3-month average daily volume of 889.7K.

    More News

    Read More
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗
    Via Chartmill
    UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗
    Via Chartmill
    News headline image
    UroGen (URGN) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Urogen Pharma Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Via The Motley Fool
    News headline image
    UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
    From UroGen Pharma Ltd.
    Via GlobeNewswire
    News headline image
    UroGen (URGN) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    UroGen Pharma to Present at Upcoming Investor Conferences
    From UroGen Pharma Ltd.
    Via GlobeNewswire

    Frequently Asked Questions

    Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
    Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
    What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
    UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
    The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
    What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
    The current price of UroGen Pharma Ltd. - Ordinary Shares is 38.26
    When was UroGen Pharma Ltd. - Ordinary Shares last traded?
    The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 10/13/26 04:00 PM ET
    What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
    The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 1.38B
    How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
    UroGen Pharma Ltd. - Ordinary Shares has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.